Q4 2019 13F Holders as of 31 Dec 2019
-
Type / Class
-
Debt / NOTE 0.750% 5/1
-
Unit price / market price
-
$0.8655
-
Total 13F principal
-
$735,378,302
-
Principal change
-
-$25,371,698
-
Total reported value
-
$636,640,277
-
Number of holders
-
48
-
Value change
-
-$20,703,526
-
Number of buys
-
20
-
Number of sells
-
16
Institutional Holders of LIGAND PHARMACEUTICALS INC - NOTE 0.750% 5/1 as of Q4 2019
As of 31 Dec 2019 LIGAND PHARMACEUTICALS INC - NOTE 0.750% 5/1 had 48 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of $735,378,302 principal (par value or face value) of the bond of the company.
Largest 10 bondholders included Allianz Asset Management GmbH, CANYON CAPITAL ADVISORS LLC, STEELHEAD PARTNERS LLC, ADVENT CAPITAL MANAGEMENT /DE/, CAMDEN ASSET MANAGEMENT L P /CA, WOLVERINE ASSET MANAGEMENT LLC, CITADEL ADVISORS LLC, UBS ASSET MANAGEMENT AMERICAS INC, Polar Capital LLP, and STATE STREET CORP.
This table shows 48 bond principal holders of the security as of 31 Dec 2019.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.